A U.S. advisory panel said Friday that it has rejected a medicine from Jazz Pharmaceuticals Inc. (NASDAQ: JAZZ) designed to ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE